<DOC>
	<DOCNO>NCT00294385</DOCNO>
	<brief_summary>The purpose study compare Time To Disease Progression ( TTDP ) patient unresectable , locally recurrent metastatic breast cancer treat concomitant Docetaxel plus Gemcitabine patient treat sequential therapy Docetaxel follow Gemcitabine .</brief_summary>
	<brief_title>Study Comparing Concomitant Docetaxel + Gemcitabine Sequential Therapy Docetaxel Followed Gemcitabine</brief_title>
	<detailed_description>This open , multicenter , two-armed Phase III study Patients randomize either follow two arm : Arm A ( concomitant arm ) , Gemcitabine 1000 mglm2 administer intravenously Days 1 8 , repeat Day 22 . Docetaxel 75 mg/m2 give Day 8 ( Gemcitabine ) , repeat Day 22 . This 3-week schedule defines cycle treatment arm . Overall 8 cycle administer . Arm B ( sequential arm ) four cycle Docetaxel 100 mg/m2 Day 1 , repeat Day 22 , follow four cycle Gemcitabine 1250 mg/m2 Day 1 8 , repeat Day 22 , give . Both drug administer 3-week schedule . Bimonthly follow-up patient without confirmed disease progression progression disease . Long-term follow-up patient confirm disease progression do 4 interval . For therapy control frequent blood chemistry hematology , physical examination , weight control , potential adverse event image procedure ( CT , X-ray , MRI , Bone scan ) foreseen .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Patients histologic cytologic diagnosis breast cancer evidence unresectable , locally recurrent , metastatic disease . Females , 18 75 year age pretreated ONE anthracyclines contain chemotherapy either neoadjuvant/adjuvant 1st line metastatic setting enrol study Patients clinically measurable lesion enrol study . Measurability determine accord RECIST criterion Performance status 70 high Karnofsky Performance Scale Adequate bone marrow reserve Adequate liver function Adequate renal function Informed consent form patient guardian Childbearing potential either terminate surgery , radiation , menopause , use approve contraceptive method Active infection ( discretion investigator ) . Known suspected brain metastasis require steroid radiation treatment . Pregnancy ( recent negative urine pregnancy test premenopausal patient mandatory ) Breastfeeding Serious concomitant systemic disorder incompatible study ( discretion investigator ) . Second primary malignancy ( except situ carcinoma cervix adequately treat basal cell carcinoma skin ) . Bone metastasis , pleural effusion , ascites site disease . Bone marrow transplantation autologous stern cell infusion follow highdose chemotherapy adjuvant metastatic disease .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Docetaxel</keyword>
</DOC>